During the last session, Dianthus Therapeutics Inc (NASDAQ:DNTH)’s traded shares were 0.33 million, with the beta value of the company hitting 1.83. At the end of the trading day, the stock’s price was $24.49, reflecting an intraday gain of 1.49% or $0.36. The 52-week high for the DNTH share is $33.77, that puts it down -37.89 from that peak though still a striking 25.11% gain since the share price plummeted to a 52-week low of $18.34. The company’s market capitalization is $724.82M, and the average intraday trading volume over the past 10 days was 0.2 million shares, and the average trade volume was 260.23K shares over the past three months.
Dianthus Therapeutics Inc (DNTH) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.17. DNTH has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.76.
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
Dianthus Therapeutics Inc (DNTH) registered a 1.49% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.49% in intraday trading to $24.49, hitting a weekly high. The stock’s 5-day price performance is 6.25%, and it has moved by 21.78% in 30 days. Based on these gigs, the overall price performance for the year is 4.84%. The short interest in Dianthus Therapeutics Inc (NASDAQ:DNTH) is 5.91 million shares and it means that shorts have 22.17 day(s) to cover.
The consensus price target of analysts on Wall Street is $52, which implies an increase of 52.9% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $52 and $52 respectively. As a result, DNTH is trading at a discount of -112.33% off the target high and -112.33% off the low.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
In the rating firms’ projections, revenue will increase 91.28% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 859.7k as predicted by 10 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 796k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 457k and 874k respectively. In this case, analysts expect current quarter sales to grow by 88.12% and then drop by -8.92% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 29.95%. While earnings are projected to return 69.69% in 2025, the next five years will return 23.26% per annum.
DNTH Dividends
Dianthus Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
Dianthus Therapeutics Inc insiders own 8.76% of total outstanding shares while institutional holders control 113.19%, with the float percentage being 124.05%.
Also, the Mutual Funds coming in first place with the largest holdings of Dianthus Therapeutics Inc (DNTH) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that Fidelity Growth Company Fund owns about 933.52 shares. This amounts to just over 3.15 percent of the company’s overall shares, with a $22.86 million market value. The same data shows that the other fund manager holds slightly less at 789.09, or about 2.67% of the stock, which is worth about $19.32 million.
